Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer

被引：4
|
作者：
Tombal, Bertrand
Borre, Michael
Rathenborg, Per
Werbrouck, Patrick
Heidenreich, Axel
Iversen, Peter
Baskin-Bey, Edwina S.
Perabo, Frank
Phung, De
Smith, Matthew Raymond
机构：
[1] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium
[2] Arhus Univ Hosp, Dept Urol, Skejby, Denmark
[3] Herlev Hosp, DK-2730 Herlev, Denmark
[4] AZ Groeninge Kortrijk, Kortrijk, Belgium
[5] Klin & Poliklin Urol, North Rhine Westphalia, Germany
[6] Univ Copenhagen, Rigshosp, DK-2100 Copenhagen, Denmark
[7] Astellas Pharma Europe Ltd, Staines, England
[8] Astellas Pharma Inc, Leiderdorp, Netherlands
[9] Astellas Pharma Europe BV, Leiderdorp, Netherlands
[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Obesity, diabetes and aggressive prostate cancer hormone-naive at initial diagnosis
    Di Francesco, Simona
    Tenaglia, Raffaele L.
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2013, 66 (04) : 423 - 427
  • [32] Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
    Recine, Federica
    Sternberg, Cora N.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) : 355 - 364
  • [33] Metastatic Burden in Hormone-Naive Prostate Cancer: A Tale of Two Subgroups
    Haran, A. M.
    Ali, A.
    Clarke, N. W.
    CLINICAL ONCOLOGY, 2020, 32 (03) : 209 - 212
  • [34] THE EFFECT OF TIME TO CASTRATION RESISTANCE ON SURVIVAL IN PATIENTS WITH METASTATIC HORMONE-NAIVE PROSTATE CANCER: A MULTICENTER RETROSPECTIVE STUDY
    Tokui, Noriko
    Hatakeyama, Shingo
    Narita, Satoshi
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Ohyama, Chikara
    JOURNAL OF UROLOGY, 2020, 203 : E564 - E565
  • [35] Zoledronic acid for hormone-naive prostate cancer with bone metastasis.
    Nozawa, Masahiro
    Hara, Isao
    Nagao, Kazuhiro
    Matsuyama, Hideyasu
    Uemura, Hirotsugu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? No, Not Yet
    Armstrong, Andrew J.
    ONCOLOGY-NEW YORK, 2014, 28 (10): : 881 - +
  • [37] Results of a phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naive patients with metastatic hormone refractory prostate cancer (HRPC)
    DeJager, R.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H. B.
    Earhart, R.
    EJC SUPPLEMENTS, 2008, 6 (12): : 67 - 67
  • [38] Trends in the use of local intervention for metastatic hormone-naive prostate cancer: A multicenter retrospective study
    Tanaka, Ryuma
    Hatakeyama, Shingo
    Narita, Shintaro
    Sakurai, Toshihiko
    Tanaka, Toshikazu
    Miura, Hikari
    Oishi, Takuya
    Kawamura, Sadafumi
    Hoshi, Senji
    Ishidoya, Shigeto
    Mitsuzuka, Koji
    Ito, Akihiro
    Tsuchiya, Norihiko
    Habuchi, Tomonori
    Ohyama, Chikara
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (11) : 969 - 976
  • [39] A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naive prostate cancer (mHNPC): ZZFIRST.
    Mateo, Joaquin
    Borque, Angel
    Castellano, Daniel E.
    Castro, Elena
    Climent Duran, Miguel Angel A.
    Font, Albert
    Lorente, David
    Mellado, Begona
    Rodriguez-Vida, Alejo
    Cuadras, Merce
    Planas, Jacques
    Casanova Salas, Irene
    Cordoba, Sarai
    Gonzalez, Lucila
    Martinez de Falcon, Marta
    Fernandez, Melissa
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Perez-Lopez, Raquel
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [40] Health care cost in hormone-naive and hormonally pretreated patients with prostate cancer treated with degarelix
    Wolff, Johannes
    Tolle, Alexander
    Gedamke, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345